Electrophysiologic Properties of Furosemide in Man

Gould, Lawrence; Chokshi, A.B.; Patel, S.; Gomes, G.I.
January 1983
Angiology;Jan1983, Vol. 34 Issue 1, p53
Academic Journal
Furosemide has been extensively used in the treatment of heart failure and its effect on cardiovascular dynamics are well established. Clinical relief of the symptoms of pulmonary congestion frequently precedes any demonstrable diuretic effect, suggesting that extra renal factors may also be involved. More recent studies on the extra-renal action of furosemide showed an increase of venous capacitance as an early hemodynamic effect of the drug. In spite of furosemides wide use in the treatment of heart failure and hypertension, there is no information on the electrophysiologic properties of the drug in man. The present study involving 8 human subjects was undertaken to determine what effect intravenously administered furosemide has on the human conduction system.


Related Articles

  • Help for Failing Hearts.  // Medical Update;2005, Vol. 30 Issue 10, p5 

    Focuses on the results of a medical study which evaluated the efficiency of external counterpulsation therapy in preventing and treating heart diseases in U.S. patients in April 2005. Advantages of the treatment over drug therapy; Assessment of the effect of the therapy on patients with...

  • Use, tolerability and compliance of spironolactone in the treatment of heart failure. Lachaine, Jean; Beauchemin, Catherine; Ramos, Elodie // BMC Clinical Pharmacology;2011, Vol. 11 Issue 1, p4 

    Background: Risk of morbidity and mortality in patients with severe heart failure (HF) is reduced by blockade of aldosterone receptors with spironolactone. However, benefits of spironolactone are potentially limited by treatment compliance and adverse events profile. The aim of this study was to...

  • Levosimendan in the treatment of AHF: lessons from surveys and clinical trials. Mebazaa, Alexandre; Delgado, Juan F.; Franco, Fatima; Toller, Wolfgang; Parissis, John; Pini, Daniela; Giannakoulas, George; Gorjup, Vojka; Karpati, Peter C.J.; Follath, Ferenc; Nieminen, Markku S. // European Journal of Heart Failure. Supplements;Jun2008, Vol. 7 Issue 2, p228 

    Abstract: Acute heart failure (AHF) is a primary cause of hospital admission throughout the world. Several acute heart failure registries have been conducted in the United States (U.S.) and Europe assessing the clinical presentation of AHF in the real world. Of the five large registries two were...

  • Levosimendan: a decade of experience in Europe built on years of evidence. Parissis, John; Toller, Wolfgang; Franco, Fatima; Delgado, Juan F.; Danou, Fotini; Llorens-Soriano, Pere; Karpati, Peter C.J.; Nieminen, Markku S.; Mebazaa, Alexandre; Follath, Ferenc // European Journal of Heart Failure. Supplements;Jun2008, Vol. 7 Issue 2, p234 

    Abstract: Recent European Society of Cardiology''s (ESC) guidelines on the diagnosis and treatment of acute heart failure (AHF), suggest that an essential target in the management of these patients is to improve symptoms within hours, which should persist until hospital release, also protecting...

  • Beyond dyssynchrony in cardiac resynchronisation therapy. Chung, A.; Sutton, A.; Henein, M. Y. // Heart;Aug2008, Vol. 94 Issue 8, p991 

    Cardiac resynchronisation therapy (CRT) in the form of biventricular pacing has emerged as a therapeutic option for patients with refractory heart failure. Patient selection and optimisation for CRT is based on the measurement of electromechanical ventricular dyssynchrony by electrocardiogram...

  • Natriuretic peptides and the heart: current and future implications for clinical biochemistry. Penney, M D // Annals of Clinical Biochemistry;Nov2005, Vol. 42 Issue 6, p432 

    The measurement of B-type natriuretic peptides in plasma is under intense promotion as a method of screening for heart failure. This article provides a historical context for this contention, and attempts to highlight what practical problems may be encountered in establishing a screening service...

  • Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study. Cleland, J. G. F.; Freemantle, N.; Daubert, J.-C.; Toff, W. D.; Leisch, F.; Tavazzi, L. // Heart;Mar2008, Vol. 94 Issue 3, p278 

    Background: Cardiac resynchronisation therapy (CAT) improves symptoms and prognosis in patients with heart failure and cardiac dyssynchrony. Guidelines from the National Institute of Health and Clinical Excellence in the United Kingdom recommend CAT for patients with recent or persistent...

  • Trial of a family-based education program for heart failure patients in rural Thailand. Srisuk, Nittaya; Cameron, Jan; Ski, Chantal F.; Thompson, David R. // BMC Cardiovascular Disorders;2014, Vol. 14 Issue 1, p1 

    Background Heart failure (HF) significantly impacts on the daily lives of patients and their carers. In Western society HF education programs have increased patient and carer knowledge and improved health-related quality of life. However, there is a paucity of such evidence in Asia. For example,...

  • Switching to Once-Daily Evidence-Based β-Blockers in Patients With Systolic Heart Failure or Left Ventricular Dysfunction After Myocardial Infarction. Albert, Nancy M. // Critical Care Nurse;Dec2007, Vol. 27 Issue 6, p62 

    The article proposes the simplification of β-blocker regimen for patients with systolic heart failure by using evidence-based β-blockers with once-daily dosing to improve patient medication adherence. Carvedilol CR, metaprolol succinate and bisoprolol are once-daily β-blocker therapies...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics